Cancer Treatment Reviews
Volume 30, Issue 8 , Pages 715-720, December 2004

Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer:☆☆☆☆☆☆

Abstracted from: Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42

Johns Hopkins Hospital, 600 North Wolfe Street, Halsted 614, Baltimore, MD 21287-5614, USA

published online 25 October 2004.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Sources of funding: Genentech.

☆☆ For Correspondence: Dr. Hurwitz, Department of Medical Oncology and Transplantation, Duke University Medical Center, Room 3802, Red Zone, Durham, NC 27710. E-mail: hurwi004@mc.duke.edu.

☆☆☆ Abstract provided by Bazian Ltd, London.

PII: S0305-7372(04)00149-5

doi:10.1016/j.ctrv.2004.09.003

Cancer Treatment Reviews
Volume 30, Issue 8 , Pages 715-720, December 2004

Article Tools